Edition:
United Kingdom

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

72.79EUR
2:52pm GMT
Change (% chg)

€-0.30 (-0.41%)
Prev Close
€73.09
Open
€72.86
Day's High
€73.20
Day's Low
€72.74
Volume
1,035,992
Avg. Vol
2,533,146
52-wk High
€80.44
52-wk Low
€62.88

Latest Key Developments (Source: Significant Developments)

Sanofi: FDA Approves Expanded Use Of Adacel (Tdap) Vaccine For Repeat Vaccination
Tuesday, 15 Jan 2019 

Jan 15 (Reuters) - SANOFI SA ::ANNOUNCED ON MONDAY FDA APPROVAL OF EXPANDED USE OF ADACEL® (TDAP) VACCINE FOR REPEAT VACCINATION.FIRST AND ONLY VACCINE APPROVED IN THE U.S. FOR REPEAT VACCINATION 8 YEARS OR MORE AFTER THE FIRST VACCINATION TO HELP PROTECT AGAINST TETANUS, DIPHTHERIA AND PERTUSSIS.APPROVAL BASED ON CLINICAL STUDY OF MORE THAN 1,300 ADULTS DEMONSTRATING A SECOND DOSE OF ADACEL VACCINE IS SAFE AND EFFECTIVE WHEN ADMINISTERED 8-12 YEARS AFTER A PREVIOUS DOSE.  Full Article

New England Journal Of Medicine Publishes Positive Results Of Cablivi (Caplacizumab) Trial
Wednesday, 9 Jan 2019 

Jan 10(Reuters) - SANOFI SA ::ANNOUNCED ON WEDNESDAY THAT HERCULES PHASE 3 TRIAL MET ITS PRIMARY ENDPOINT.CABLIVI WAS ASSOCIATED WITH SIGNIFICANT REDUCTION IN ATTP-RELATED DEATH, RECURRENCE, OR AT LEAST ONE MAJOR THROMBOEMBOLIC EVENT WHILE PATIENTS WERE ON TREATMENT.DURING THE OVERALL STUDY PERIOD, PATIENTS EXPERIENCED A SIGNIFICANTLY LOWER NUMBER OF ATTP RECURRENCES (67 PERCENT REDUCTION) COMPARED TO PLACEBO (P<0.001).RESULTS SHOWED CLINICALLY MEANINGFUL REDUCTION IN THE USE OF PLASMA EXCHANGE IN PATIENTS TREATED (AVERAGE 5.8 DAYS; 38 PCT REDUCTION) VERSUS PLACEBO (9.4 DAYS).  Full Article

AbSci Announces Collaboration With Sanofi
Wednesday, 9 Jan 2019 

Jan 9 (Reuters) - Sanofi SA ::ABSCI SAYS ANNOUNCED A COLLABORATION WITH SANOFI.ABSCI SAYS COLLABORATION WILL TAKE PLACE AT ABSCI AND BE FUNDED BY SANOFI.  Full Article

Acer Therapeutics Announces In-License Of Osanetant From Sanofi
Wednesday, 2 Jan 2019 

Jan 2 (Reuters) - Acer Therapeutics Inc ::ACER THERAPEUTICS ANNOUNCES IN-LICENSE OF OSANETANT FROM SANOFI.ACER THERAPEUTICS INC - HAS ENTERED INTO AN EXCLUSIVE LICENSE AGREEMENT WITH SANOFI TO ACQUIRE WORLDWIDE RIGHTS TO OSANETANT.ACER THERAPEUTICS INC - PLANS TO INITIALLY PURSUE DEVELOPMENT OF OSANETANT AS A POTENTIAL TREATMENT FOR CERTAIN NEUROENDOCRINE-RELATED DISORDERS.ACER THERAPEUTICS INC - FINANCIAL TERMS OF LICENSE AGREEMENT WERE NOT DISCLOSED.  Full Article

Opiant Pharmaceuticals Licenses Novel Cb-1 Receptor Antagonist For Treatment Of Acute Cannabinoid Overdose From Sanofi
Wednesday, 26 Dec 2018 

Dec 26 (Reuters) - Opiant Pharmaceuticals Inc ::OPIANT PHARMACEUTICALS LICENSES NOVEL CB-1 RECEPTOR ANTAGONIST FOR TREATMENT OF ACUTE CANNABINOID OVERDOSE FROM SANOFI.OPIANT PHARMACEUTICALS INC - UNDER TERMS OF TRANSACTION, OPIANT WILL PAY SANOFI AN UPFRONT FEE OF $500,000.OPIANT PHARMACEUTICALS INC - OPIANT WILL ASSUME ALL DEVELOPMENT AND COMMERCIAL RESPONSIBILITIES RELATED TO DRINABANT..OPIANT PHARMACEUTICALS INC - FURTHER PAYMENTS CONTINGENT UPON OPIANT ACHIEVING CERTAIN CLINICAL, REGULATORY AND SALES MILESTONES.  Full Article

Canada Completes Abuse Of Dominance Investigation Into Practices Of Celgene, Pfizer And Sanofi
Thursday, 20 Dec 2018 

Dec 20 (Reuters) - Celgene Corp ::COMPETITION BUREAU COMPLETES ABUSE OF DOMINANCE INVESTIGATION INTO PRACTICES OF CELGENE, PFIZER AND SANOFI.COMPETITION BUREAU OF CANADA - INSUFFICIENT EVIDENCE TO SHOW COMPETITION SUBSTANTIALLY LESSENED/PREVENTED IN INVESTIGATION INTO CELGENE, PFIZER, SANOFI.COMPETITION BUREAU OF CANADA - BUREAU IS UNABLE TO CONCLUDE THAT COMPETITION ACT HAS BEEN CONTRAVENED.  Full Article

Sanofi Dengvaxia Vaccine Approved For Prevention Of Dengue In Europe
Wednesday, 19 Dec 2018 

Dec 19 (Reuters) - SANOFI SA ::REG-DENGVAXIA® VACCINE APPROVED FOR PREVENTION OF DENGUE IN EUROPE.DENGVAXIA WILL BE AVAILABLE IN EUROPE TO PREVENT DENGUE DISEASE IN INDIVIDUALS 9-45 YEARS OF AGE.  Full Article

Sanofi to transfer U.S. stock exchange listing to Nasdaq
Tuesday, 18 Dec 2018 

Dec 18 (Reuters) - Sanofi SA ::SANOFI TO TRANSFER U.S. STOCK EXCHANGE LISTING TO NASDAQ.SANOFI - TRANSITION WILL NOT IMPACT COMPANY'S PRIMARY LISTING ON EURONEXT.SANOFI - SANOFI'S ADSS ARE EXPECTED TO BEGIN TRADING AS A NASDAQ-LISTED SECURITY AT MARKET OPEN ON JANUARY 2, 2019.SANOFI - WILL CONTINUE TO BE LISTED UNDER TICKER SYMBOL "SNY".  Full Article

VIVUS Entered Into Amendment To Commercial Supply Agreement With Sanofi Chimie
Wednesday, 12 Dec 2018 

Dec 12 (Reuters) - Vivus Inc ::VIVUS INC - ENTERED INTO AMENDMENT TO COMMERCIAL SUPPLY AGREEMENT WITH SANOFI CHIMIE.VIVUS INC - BEGINNING JAN. 1, SANOFI CHIMIE TO EXCLUSIVELY MANUFACTURE, SUPPLY API FOR AVANAFIL IN COUNTRIES WHERE CO HAS RIGHT TO SELL AVANAFIL.VIVUS INC - BEGINNING JAN. 1, YEARLY MINIMUM QUANTITIES OF API VIVUS MUST PURCHASE FROM SANOFI CHIMIE WILL BE ADJUSTED.VIVUS INC - CO, SANOFI CHIMIE AGREED TO EXTEND TERM OF COMMERCIAL SUPPLY AGREEMENT UNTIL DEC. 31, 2023.  Full Article

Immune Design Says Sanofi US Services Elected To Terminate License Agreement
Monday, 10 Dec 2018 

Dec 10 (Reuters) - Immune Design Corp ::IMMUNE DESIGN SAYS ON DEC 6, RECEIVED NOTICE FROM SANOFI US SERVICES, THAT IT ELECTED TO TERMINATE LICENSE AGREEMENT DATED AS OF AUGUST 6, 2014.IMMUNE DESIGN - TERMINATION OF LICENSE AGREEMENT WILL BE EFFECTIVE ON JUNE 6, 2019; IS RESULT OF PORTFOLIO PRIORITIZATION BY SANOFI - SEC FILING.IMMUNE DESIGN CORP - TERMINATION IS UNRELATED TO COMPANY'S COLLABORATION WITH SANOFI PASTEUR.IMMUNE DESIGN - RECOGNIZED NO MILESTONE REVENUE UNDER LICENSE AGREEMENT WITH SANOFI US SERVICES FOR 9 MONTHS ENDED SEPT 30, 2018.  Full Article

U.S. insulin costs per patient nearly doubled from 2012 to 2016 -study

Jan 22 The cost of insulin for treating type 1 diabetes in the United States nearly doubled over a five-year period, underscoring a national outcry over rising drug prices, according to a new analysis shared with Reuters.